Evaluation of the antitumor activity of NOV202, a novel microtubule targeting and vascular disrupting agent
Linda Rickardson,1 Emma Kutvonen,2 Satu Orasniemi,2 Marita Högberg,1 Marko J Kallio,2,3 Stefan Rehnmark1 1Noviga Research AB, Södertälje, Sweden; 2Department of Physiology, Institute of Biomedicine, University of Turku, 3Centre for Biotechnology, University of Turku, Turku, Finland Purpose: Overall,...
Saved in:
Main Authors: | Rickardson L (Author), Kutvonen E (Author), Orasniemi S (Author), Högberg M (Author), Kallio MJ (Author), Rehnmark S (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2017-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Phase I and pharmacokinetic study of the vascular‐disrupting agent CKD‐516 (NOV120401) in patients with refractory solid tumors
by: Hark Kyun Kim, et al.
Published: (2020) -
Tubulin/microtubules as novel clozapine targets
by: Mizuki Hino, et al.
Published: (2022) -
The microtubule cytoskeleton: An old validated target for novel therapeutic drugs
by: Laurence Lafanechère
Published: (2022) -
Discovery of facile amides-functionalized rhodanine-3-acetic acid derivatives as potential anticancer agents by disrupting microtubule dynamics
by: Xiang Zhou, et al.
Published: (2021) -
WXJ-202, a novel Ribociclib derivative, exerts antitumor effects against breast cancer through CDK4/6
by: Jing Ji, et al.
Published: (2023)